Option chain shows key data for Iterum Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Iterum Therapeutics.

Iterum Therapeutics (NASDAQ:ITRM) Stock, Option Chain

Iterum Therapeutics

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Wall-Street-ai7-1

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Commodities

Forex

Econ #s

Economics

Tech

ETFs

$BTC

AFRM

AMZN

AVTR

CBOE

SPDR Dow Jones Industrial Average ETF Trust

EXPE

FTNT

GPRE

ILMN

ITRM

MPWR

PAGP

PINS

POST

PRLB

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

ROAD

SSNC

iShares Trust Barclays 20+ Year Treasury Bond Fund

TTWO

UBER

ULCC

PowerShares DB US Dollar Index Bullish Fund

VRSN

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appetite. 

Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman&#39;s Tweet: What&#39;s Driving Markets Friday?

Pop Culture’s Health Boost

Biotech

News

Health Care

General

Iterum Therapeutics&#39; Orlynvah receives FDA approval for treating uncomplicated UTIs in adult women, marking its first approved indication and a U.S. first for oral penems.

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships

pharmaceuticals therapeutics medicine

Movers & Shakers

Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin.

Why Iterum Therapeutics Stock Is Trending Today

Iterum Therapeutics PLC

Press Releases

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Earnings

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Iterum Therapeutics Regains Full Nasdaq Compliance

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

China Pharma Holding

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

IGC Pharma

Ikena Oncology

Opus Genetics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

NRX Pharmaceuticals

Nutriband

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

HC Wainwright & Co.

Comments

Iterum Therapeutics

Iterum Therapeutics (ITRM) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell